Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

Status:
Completed
Trial end date:
2011-07-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and subjects with moderate to severe psoriasis (PsO).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
AstraZeneca